Stabilization patterns and variability of hs-CRP, NT-proBNP and ST2 during 1 year after acute coronary syndrome admission: results of the BIOMArCS study

Victor J. van den Berg, Victor A. W. M. Umans, Milos Brankovic, Rohit M. Oemrawsingh, Folkert W. Asselbergs, Pim van der Harst, Imo E. Hoefer, Bas Kietselaer, Harry J. G. M. Crijns, Timo Lenderink, Anton J. Oude Ophuis, Ron H. van Schaik, Isabella Kardys, Eric Boersma*, K. Martijn Akkerhuis, BIOMArCS Investigators

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objectives: Details of the biological variability of high-sensitivity C-reactive protein (hs-CRP), N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and ST2 are currently lacking in patients with acute coronary syndrome (ACS) but are crucial knowledge when aiming to use these biomarkers for personalized risk prediction. In the current study, we report post-ACS kinetics and the variability of the hs-CRP, NT-proBNP and ST2.

Methods: BIOMArCS is a prospective, observational study with high frequency blood sampling during 1 year post-ACS. Using 1507 blood samples from 191 patients that remained free from adverse cardiac events, we investigated post-ACS kinetics of hs-CRP, NT-proBNP and S12. Biological variability was studied using the samples collected between 6 and 12 months after the index ACS, when patients were considered to have stable coronary artery disease.

Results: On average, hs-CRP rose peaked at day 2 and rose well above the reference value. ST2 peaked immediately after the ACS but never rose above the reference value. NT-proBNP level rose on average during the first 2 days post-ACS and slowly declined afterwards. The within-subject variation and relative change value (RCV) of ST2 were relatively small (13.8%, RCV 39.7%), while hs-CRP (41.9%, lognormal RCV 206.1/-67.3%) and NT-proBNP (39.0%, lognormal RCV 185.2/-6/1.9%) showed a considerable variation.

Conclusions: Variability of hs-CRP and NT-proBNP within asymptomatic and clinically stable post-ACS patients is considerable. In contrast, within-patient variability of ST2 is low. Given the low within-subject variation, ST2 might be the most useful biomarker for personalizing risk prediction in stable post-ACS patients.

Original languageEnglish
Pages (from-to)2099-2106
Number of pages8
JournalClinical Chemistry and Laboratory Medicine
Volume58
Issue number12
DOIs
Publication statusPublished - Dec 2020

Keywords

  • acute coronary syndrome (ACS)
  • C-reactive protein (CRP)
  • myocardial infarction
  • N-terminal prohormone of brain natriuretic peptide (NTproBNP)
  • ST2
  • variability
  • C-REACTIVE PROTEIN
  • CHRONIC HEART-FAILURE
  • ACUTE MYOCARDIAL-INFARCTION
  • NATRIURETIC PEPTIDE
  • SOLUBLE ST2
  • BIOLOGICAL VARIATION
  • PROGNOSTIC VALUE
  • ARTERY-DISEASE
  • TERMINAL PROBNP
  • MORTALITY

Cite this